Oral delivery of highly lipophilic poorly water-soluble drugs: Spray-dried dispersions to improve oral absorption and enable high-dose toxicology studies of a P2Y1 antagonist

Journal of Pharmaceutical Sciences

Volumn 103, Issue 12, 2014, Pages 3924-3931

  Chen, Xue Qing ^a   Stefanski, Kevin ^a   Shen, Hong ^a   Huang, Christine ^a   Caporuscio, Christian ^a   Yang, Wu ^a   Lam, Patrick ^a,b   Su, Ching ^a   Gudmundsson, Olafur ^a   Hageman, Michael ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Lam Drug Discovery Consulting LLC   (United States)

Author keywords

Absorption; Amorphous; Dissolution; Solubility; Spray drying

Indexed keywords

BMS B; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; PURINERGIC P2Y RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; METHYLCELLULOSE; SOLUTION AND SOLUBILITY; WATER;

ANIMAL EXPERIMENT; ARTICLE; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MEGADOSE; DRUG SOLUBILITY; DRUG SOLUTION; GLASS TRANSITION TEMPERATURE; HAPLORHINI; IN VIVO STUDY; LIPOPHILICITY; LOW DRUG DOSE; MALE; NONHUMAN; PARTICLE SIZE; PH; POWDER; PRECIPITATION; RAT; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; SUSPENSION; THERMAL ANALYSIS; TOXICOLOGY; X RAY POWDER DIFFRACTION; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; CHEMISTRY; MACACA FASCICULARIS; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES; SOLUBILITY; SOLUTION AND SOLUBILITY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; HAPLORHINI; MACACA FASCICULARIS; MALE; METHYLCELLULOSE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SOLUTIONS; WATER;

EID: 84914820977     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24199     Document Type: Article

References (30)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3-25.
2. Lipinski CA. 2002. Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev 5:82-85.
3. Serajuddin AT. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88(10):1058-1066.
4. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50(1):47-60.
5. Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JA. 2008. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: An overview. Mol Pharm 5(6):1003-1019.
6. Kennedy M, Hu J, Gao P, Li L, Ali-Reynolds A, Chal B, Gupta V, Ma C, Mahajan N, Akrami A, Surapaneni S. 2008. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: A case study. Mol Pharm 5(6):981-993.
7. Fakes MG, Vakkalagadda BJ, Qian F, Desikan S, Gandhi RB, Lai C, Hsieh A, Franchini MK, Toale H, Brown J. 2009. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. Int J Pharm 370(1-2):167-174.
8. Engers D, Teng J, Jimenez-Novoa J, Gent P, Hossack S, Campbell C, Thomson J, Ivanisevic I, Templeton A, Byrn S, Newman A. 2010. A solid-state approach to enable early development compounds: Selection and animal bioavailability studies of an itraconazole amorphous solid dispersion. J Pharm Sci 99(9):3901-3922.
9. Onoue S, Uchida A, Takahashi H, Seto Y, Kawabata Y, Ogawa K, Yuminoki K, Hashimoto N, Yamada S. 2011. Development of high-energy amorphous solid dispersion of nanosized nobiletin, a citrus polymethoxylated flavone, with improved oral bioavailability. J Pharm Sci 100(9):3793-3801.
10. Onoue S, Kojo Y, Aoki Y, Kawabata Y, Yamauchi Y, Yamada S. 2012. Physicochemical and pharmacokinetic characterization of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid and improved oral bioavailability. Drug Metab Pharmacokinet 27:379-387.
11. Wilson M, Williams MA, Jones DS, Andrews GP. 2012. Hotmelt extrusion technology and pharmaceutical application. Ther Deliv 3(6):787-797.
12. Masters K. 1985. Spray drying handbook. 4th ed. New York: Halstead Press.
13. Cal K, Sollohub K. 2010. Spray drying technique. I: Hardware and process parameters. J Pharm Sci 99(2):575-586.
14. Sollohub K, Cal K. 2010. Spray drying technique: II. Current applications in pharmaceutical technology. J Pharm Sci 99(2):587-597.
15. Newman A, Knipp G, Zografi G. 2012. Assessing the performance of amorphous solid dispersions. J Pharm Sci 101(4):1355-1377.
16. Curatolo W, Nightingale JA, Herbig SM. 2009. Utility of hydroxypropylmethylcellulose acetate succinate (HPMCAS) for initiation and maintenance of drug supersaturation in the GI milieu. Pharm Res 26(6):1419-1431.
17. Leane MM, Sinclair W, Qian F, Haddadin R, Brown A, Tobyn M, Dennis AB. 2013. Formulation and process design for a solid dosage form containing a spray-dried amorphous dispersion of ibipinabant. Pharm Dev Technol 18:359-366.
18. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17(4):397-404.
19. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. 2010. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J Pharm Sci 99(3):1254-1264.
20. Hancock BC, Shamblin SL, Zografi G. 1995. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res 12(6):799-806.
21. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86(1):1-12.
22. Yu L. 2001. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev 48(1):27-42.
23. Bhugra C, Pikal MJ. 2008. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci 97(4):1329-1349.
24. Yoshioka M, Hancock BC, Zografi G. 1995. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J Pharm Sci 84(8):983-986.
25. Konno H, Taylor LS. 2006. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci 95(12):2692-2705.
26. Qian F, Wang J, Hartley R, Tao J, Haddadin R, Mathias N, Hussain M. 2012. Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications. Pharm Res 29(10):2765-2776.
27. Yang W, Wang Y, Lai A, Qiao JX, Wang TC, Hua J, Price LA, Shen H, Chen XQ, Wong P, Crain E, Watson C, Huang CS, Seiffert DA, Rehfuss R, Wexler RR, Lam PY. 2014. Discovery of 4-Aryl-7-Hydroxyindoline based P2Y1 antagonists as novel antiplatelet agents. J Med Chem 57(14):6150-6164.
28. Qiao JX, Wang TC, Ruel R, Thibeault C, L'Heureux A, Schumacher WA, Spronk SA, Hiebert S, Bouthillier G, Lloyd J, Pi Z, Schnur DM, Abell LM, Hua J, Price LA, Liu E, Wu Q, Steinbacher TE, Bostwick JS, Chang M, Zheng J, Gao Q, Ma B, McDonnell PA, Huang CS, Rehfuss R, Wexler RR, Lam PY. 2013. Conformationally constrained orthoanilino diaryl ureas: Discovery of 1-(2-(1′-neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl)-3-(4-(trifluoromet hoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist. J Med Chem 56(22):9275-9295.
29. Jeon YT, Yang W, Qiao JX, Li L, Ruel R, Thibeault C, Hiebert S, Wang TC, Wang Y, Liu Y, Clark CG, Wong HS, Zhu J, Wu DR, Sun D, Chen BC, Mathur A, Chacko SA, Malley M, Chen XQ, Shen H, Huang CS, Schumacher WA, Bostwick JS, Stewart AB, Price LA, Hua J, Li D, Levesque PC, Seiffert DA, Rehfuss R, Wexler RR, Lam PY. 2014. Identification of 1-{2-[4-chloro-1′-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4′-pip eridine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent. Bioorg Med Chem Lett 24(5):1294-1298.
30. Dressman JB, Amidon GL, Reppas C, Shah VP. 1998. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm Res 15(1):11-22.